Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
uniQure N.V. (0EE0.L)
Amsterdam, VIC, NL
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 12 Rev. Ana. 1 EPS Ana. |
Dec 2027 11 Rev. Ana. 1 EPS Ana. |
Dec 2028 4 Rev. Ana. 1 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 5 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.45M
est: 8.74M (+19.6%)
|
25.10M
est: 18.28M (+37.3%)
|
13.11M
est: 12.60M (+4.0%)
|
11.28M
est: 12.78M (-11.7%)
|
7.28M
est: 6.22M (+17.0%)
|
37.51M
est: 116.44M (-67.8%)
|
524.00M
est: 475.82M (+10.1%)
|
106.48M
est: 30.57M (+248.3%)
|
15.84M
est: 20.88M (-24.1%)
|
27.12M
est: 39.44M (-31.2%)
|
16.10M
est: 15.78M (+2.0%)
|
20.98M
11.90M – 32.44M
+33.0% YoY
|
120.86M
68.55M – 186.86M
+476.0% YoY
|
289.52M
164.23M – 447.64M
+139.6% YoY
|
496.23M
281.48M – 767.25M
+71.4% YoY
|
628.50M
356.51M – 971.76M
+26.7% YoY
|
| EBITDA |
-72.48M
est: -5.93M (-1,122.5%)
|
-63.97M
est: -12.40M (-415.8%)
|
-69.44M
est: -8.54M (-712.7%)
|
-75.93M
est: -8.66M (-776.3%)
|
-113.79M
est: -4.22M (-2,595.3%)
|
-114.78M
est: -78.98M (-45.3%)
|
347.58M
est: -322.73M (+207.7%)
|
-108.02M
est: -20.73M (-421.0%)
|
-255.08M
est: -14.16M (-1,701.5%)
|
-160.75M
est: -26.32M (-510.8%)
|
-170.71M
est: -10.53M (-1,521.5%)
|
-14.00M
-21.65M – -7.94M
-33.0% YoY
|
-80.65M
-124.70M – -45.75M
-476.0% YoY
|
-193.21M
-298.73M – -109.59M
-139.6% YoY
|
-331.15M
-512.01M – -187.84M
-71.4% YoY
|
-419.42M
-648.49M – -237.91M
-26.7% YoY
|
| EBIT |
-68.51M
est: -5.95M (-1,050.9%)
|
-71.03M
est: -12.45M (-470.4%)
|
-76.98M
est: -8.58M (-797.2%)
|
-80.91M
est: -8.70M (-830.0%)
|
-121.14M
est: -4.24M (-2,757.6%)
|
-125.43M
est: -79.30M (-58.2%)
|
340.28M
est: -324.05M (+205.0%)
|
-116.56M
est: -20.82M (-459.8%)
|
-266.98M
est: -14.22M (-1,777.8%)
|
-173.39M
est: -26.43M (-556.1%)
|
-185.47M
est: -10.57M (-1,654.3%)
|
-14.06M
-21.74M – -7.98M
-33.0% YoY
|
-80.99M
-125.22M – -45.94M
-476.0% YoY
|
-194.01M
-299.98M – -110.05M
-139.6% YoY
|
-332.53M
-514.15M – -188.63M
-71.4% YoY
|
-421.17M
-651.20M – -238.91M
-26.7% YoY
|
| Net Income |
-79.27M
est: -162.25M (+51.1%)
|
-73.37M
est: -143.67M (+48.9%)
|
-79.26M
est: -144.10M (+45.0%)
|
-83.30M
est: -117.95M (+29.4%)
|
-124.20M
est: -135.37M (+8.3%)
|
-125.02M
est: -177.33M (+29.5%)
|
329.59M
est: 300.13M (+9.8%)
|
-126.79M
est: -182.25M (+30.4%)
|
-308.48M
est: -307.06M (-0.5%)
|
-239.56M
est: -234.73M (-2.1%)
|
-198.97M
est: -222.72M (+10.7%)
|
-210.74M
-360.37M – -92.18M
+5.4% YoY
|
-182.17M
-311.52M – -79.68M
+13.6% YoY
|
-127.06M
-217.27M – -55.58M
+30.3% YoY
|
-8.82M
-15.08M – -3.86M
+93.1% YoY
|
110.50M
48.33M – 188.96M
+1,353.4% YoY
|
| SGA |
21.42M
est: 14.40M (+48.7%)
|
26.00M
est: 30.12M (-13.7%)
|
18.09M
est: 20.76M (-12.8%)
|
18.81M
est: 21.05M (-10.7%)
|
27.54M
est: 10.26M (+168.6%)
|
31.93M
est: 191.84M (-83.4%)
|
48.99M
est: 783.94M (-93.8%)
|
46.52M
est: 50.37M (-7.6%)
|
74.59M
est: 34.39M (+116.9%)
|
38.79M
est: 77.44M (-49.9%)
|
50.70M
est: 30.98M (+63.6%)
|
41.20M
23.37M – 63.70M
+33.0% YoY
|
237.32M
134.62M – 366.94M
+476.0% YoY
|
568.51M
322.48M – 879.01M
+139.6% YoY
|
974.42M
552.73M – 1.51B
+71.4% YoY
|
1.23B
700.06M – 1.91B
+26.7% YoY
|
| EPS |
-3.59
est: -3.34 (-7.6%)
|
-2.93
est: -2.95 (+0.8%)
|
-2.94
est: -2.96 (+0.7%)
|
-2.34
est: -2.42 (+3.5%)
|
-3.11
est: -2.78 (-11.8%)
|
-2.81
est: -3.65 (+22.9%)
|
7.17
est: 6.17 (+16.2%)
|
-2.71
est: -3.75 (+27.7%)
|
-6.47
est: -6.31 (-2.5%)
|
-4.92
est: -4.08 (-20.5%)
|
-3.46
est: -3.87 (+10.7%)
|
-3.66
-6.27 – -1.60
+5.4% YoY
|
-3.17
-5.42 – -1.39
+13.6% YoY
|
-2.21
-3.78 – -0.97
+30.3% YoY
|
-0.15
-0.26 – -0.07
+93.1% YoY
|
1.92
0.84 – 3.29
+1,353.4% YoY
|
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X - Genomics & Biotechnology UCITS ETF GNOM.L | 2.08% | 1.09M | 0.50% |
| 2 | iShares Ageing Population UCITS ETF AGED.L | 0.22% | 1.94M | 0.40% |
| 3 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.19% | 137.7K | 0.35% |
| 4 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.19% | 2.06M | 0.35% |
| 5 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.19% | 855.7K | 0.40% |
| 6 | iShares Biotechnology ETF IBB | 0.19% | 17.34M | 0.44% |
| 7 | Goldman Sachs Innovate Equity ETF GINN | 0.16% | 343.6K | 0.50% |
| 8 | iShares Morningstar Small Cap Value ETF ISCV | 0.09% | 604.4K | 0.06% |
| 9 | iShares Morningstar Small-Cap ETF ISCB | 0.04% | 123.5K | 0.04% |
| 10 | Fidelity MSCI Health Care Index ETF FHLC | 0.03% | 964.8K | 0.08% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 0EE0.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
